Skip to Content
  • The Soon-Shiong Hype Machine

    I have long been suspicious of people who use the word “moonshot” in the context of biomedical research. It’s lazy shorthand for “WeR… Read More
  • Marathon’s Real Costs

    Endpoints has done a great breakdown on the actual costs that Marathon Pharmaceuticals is likely to have incurred while bringing their wildly overpriced old gen… Read More
  • Not Quite What Friends Are For

    Folks who do industrial drug research know that they’re around proprietary information, and they generally know to keep quiet about it. That can be a bit… Read More
  • Thoughts on Corruption

    I’ve had many questions about what I think of the PhARMA meeting with the new administration, but I haven’t written about it yet. That’s large… Read More
  • Eli Lilly Is a Biologics Company

    The news from Eli Lilly is not good – they’re laying off 485 people, according to filings with the state, and it appears to be completely a result o… Read More
  • The Hollywood Analogy

    Yesterday’s drug-research-is-hard screed brought a lot of responses, and I wanted to address some particular points that came up. On Twitter, Alex Tabarro… Read More
  • Vivek Ramaswamy’s Plans

    I last wrote about Vivek Ramaswamy in the context of his first company (Axovant). That one went public on the hopes for a retread Alzheimer’s drug to wor… Read More
  • Not Fun Reading

    These numbers from Deloitte are not very reassuring. They do an annual survey of spending and returns on investment in the drug industry, and this year’s… Read More
Page 1 of 10012345...102030...Last »